Allergan Unanimously Rejects Valeant’s Bid

May 12 (Bloomberg) -- Allergan board says the Valeant bid “substantially undervalues” the company and creates significant risks and uncertainties and is not in best interests of the company and shareholders. Tom Keene reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)
Korea Expected to Cut Rates Again, SocGen's Baader Says
17:34 - Klaus Baader, chief Asia-Pacific economist at Societe Generale SA, talks about central bank policies in South Korea, Australia and India. He also discusses Japan's stocks, economy and currency. He speaks with Rishaad Salamat and Angie Lau on Bloomberg Television's "Asia Edge." (Source: Bloomberg)
  • India Under Fire for Quality of Airline Pilots
  • Hard for Airlines to Shrink Their Way to Success: Herdman
  • Jefferies's Darby on Japan, China Stocks, U.S. Economy